Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295922 | 0.85 | CYP19A1 (0.64) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3295755 | 0.85 | CYP19A1 (0.62) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3297532 | 0.83 | CYP19A1 (0.65) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3297599 | 0.82 | CYP19A1 (0.62) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3295745 | 0.82 | CYP19A1 (0.62) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3298587 | 0.82 | MEN1 (0.63) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3295685 | 0.80 | CYP19A1 (0.64) | CYP19A1HTTMEN1MAPTKMT2A | |
| SCHEMBL3295921 | 0.80 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL19237534 | 0.79 | MAOB (0.63) | CYP19A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL3299637 | 0.79 | CYP19A1 (0.83) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741520-B2 | Sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1984325-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007120379-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | CYP19A1, AR, SULT2A1 | CYP19A1 1/4885HTT 3747/4885MEN1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.